Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7150/ijbs.59151 http://scihub22266oqcxt.onion/10.7150/ijbs.59151 33907515!8071776!33907515     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Biol+Sci 2021 ; 17 (6): 1521-1529 Nephropedia Template TP {{tp|p=33907515|t=2021. Developing effective siRNAs to reduce the expression of key viral genes of COVID-19 |pdf=|usr=}}{{33907515}} gab.com Text Developing effective siRNAs to reduce the expression of key viral genes of COVID-19 JO: Int J Biol Sci http://www.kidney.de/pget.php?&tw=1&pmid=33907515 #FOAvip The COVID-19 pandemic has been raging worldwide for more than a year. Many efforts have been made to create vaccines and develop new antiviral drugs to cope with the disease. Here, we propose the application of short interfering RNAs (siRNAs) to degrade the viral genome, thus reducing viral infection. By introducing the concept of the probability of binding efficiency (PBE) and combining the secondary structures of RNA molecules, we designed 11 siRNAs that target the consensus regions of three key viral genes: the spike (S), nucleocapsid (N) and membrane (M) genes of SARS-CoV-2. The silencing efficiencies of the siRNAs were determined in human lung and endothelial cells overexpressing these viral genes. The results suggested that most of the siRNAs could significantly reduce the expression of the viral genes with inhibition rates above 50% in 24 hours. This work not only provides a strategy for designing potentially effective siRNAs against target genes but also validates several potent siRNAs that can be used in the clinical development of preventative medication for COVID-19 in the future. Twit Text FOAVip Developing effective siRNAs to reduce the expression of key viral genes of COVID-19 ????Int J Biol Sci http://www.kidney.de/pget.php?&tw=1&pmid=33907515 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33907515 #FOAvip English Wikipedia <ref>{{Cite pmid|33907515}}</ref> Developing effective siRNAs to reduce the expression of key viral genes of COVID-19 #MMPMID33907515 Wu R; Luo KQ Int J Biol Sci 2021[]; 17 (6): 1521-1529 PMID33907515show ga The COVID-19 pandemic has been raging worldwide for more than a year. Many efforts have been made to create vaccines and develop new antiviral drugs to cope with the disease. Here, we propose the application of short interfering RNAs (siRNAs) to degrade the viral genome, thus reducing viral infection. By introducing the concept of the probability of binding efficiency (PBE) and combining the secondary structures of RNA molecules, we designed 11 siRNAs that target the consensus regions of three key viral genes: the spike (S), nucleocapsid (N) and membrane (M) genes of SARS-CoV-2. The silencing efficiencies of the siRNAs were determined in human lung and endothelial cells overexpressing these viral genes. The results suggested that most of the siRNAs could significantly reduce the expression of the viral genes with inhibition rates above 50% in 24 hours. This work not only provides a strategy for designing potentially effective siRNAs against target genes but also validates several potent siRNAs that can be used in the clinical development of preventative medication for COVID-19 in the future. |*Genes, Viral[MESH] |A549 Cells[MESH] |COVID-19/*virology[MESH] |Gene Expression Regulation, Viral/*physiology[MESH] |Human Umbilical Vein Endothelial Cells[MESH] |Humans[MESH] |Mutation[MESH] |Probability[MESH] |RNA, Small Interfering/*physiology[MESH] |SARS-CoV-2/*genetics[MESH]Developing effective siRNAs to reduce the expression of key viral gene(epmc).pdf DeepDyve Pubget Overpricing